Canada Gazette, Part I, Volume 160, Number 6: GOVERNMENT NOTICES
February 7, 2026
DEPARTMENT OF THE ENVIRONMENT
CANADIAN ENVIRONMENTAL PROTECTION ACT, 1999
Ministerial Condition No. 22407
Ministerial condition
(Paragraph 84(1)(a) of the Canadian Environmental Protection Act, 1999)
Whereas the Minister of the Environment and the Minister of Health (the ministers) have assessed information pertaining to the substance siloxanes and silicones, di-Me, Me 3-(2-oxiranylmethoxy)propyl, Me 3,3,3-trifluoropropyl, Chemical Abstracts Service Registry Number 3086114-77-1;
And whereas the ministers suspect that the substance is toxic or capable of becoming toxic within the meaning of section 64 of the Canadian Environmental Protection Act, 1999 (the Act),
The Minister of the Environment, pursuant to paragraph 84(1)(a) of the Act, hereby permits the manufacture or import of the substance subject to the conditions of the following annex.
Marc D’Iorio
Assistant Deputy Minister
Science and Technology Branch
On behalf of the Minister of the Environment
ANNEX
Conditions
(Paragraph 84(1)(a) of the Canadian Environmental Protection Act, 1999)
1. The following definitions apply in these ministerial conditions:
- “notifier”
- means the person who has, on December 12, 2025, provided to the Minister of the Environment the prescribed information concerning the substance, in accordance with subsection 81(1) of the Canadian Environmental Protection Act, 1999 (the Act);
- “substance”
- means siloxanes and silicones, diMe, Me 3-(2-oxiranylmethoxy)propyl, Me 3,3,3trifluoropropyl, Chemical Abstracts Service Registry Number 3086114-77-1.
2. The notifier may manufacture or import the substance subject to the present ministerial conditions.
Environmental release
3. Where any release to the environment of the substance or waste containing it occurs, the notifier shall immediately take all measures necessary to prevent any further release, and to limit the dispersion of any release. Furthermore, the notifier shall, as soon as possible in the circumstances, notify an enforcement officer or the person providing the 24-hour emergency telephone service for the province or territory where the release occurs referred to in the schedule to the Release and Environmental Emergency Notification Regulations.
Other requirements
4. The notifier shall, prior to transferring the physical possession or control of the substance to any person,
- (a) inform the person, in writing, of the terms of the present ministerial conditions; and
- (b) obtain, prior to the first transfer of the substance, written confirmation from this person that they were informed of the terms of the present ministerial conditions and agree to comply with the present ministerial conditions.
Record-keeping requirements
5. (1) The notifier shall maintain electronic or paper records, with any documentation supporting the validity of the information contained in these records, indicating
- (a) the use of the substance;
- (b) the quantity of the substance that the notifier manufactures, imports, purchases, distributes, sells and uses;
- (c) the name and address of each person to whom the notifier transfers the physical possession or control of the substance; and
- (d) the written confirmation referred to in paragraph 4(b).
(2) When the notifier learns of a change to the address referred to in paragraph (1)(c), the notifier must update the electronic or paper records mentioned in subsection (1) accordingly within 30 days after learning of the change.
(3) The notifier shall create the electronic or paper records mentioned in subsection (1) no later than 30 days after the date the information or documents become available.
(4) The notifier shall maintain the electronic or paper records mentioned in subsection (1)
- (a) in English, French, or both languages; and
- (b) at the notifier’s principal place of business in Canada, or at the principal place of business in Canada of their representative, for a period of at least five years after they are made.
(5) Any records mentioned in subsection (1) that are kept electronically must be in an electronically readable format.
Coming into force
6. The present ministerial conditions come into force on January 27, 2026.
PRIVY COUNCIL OFFICE
Appointment opportunities
We know that our country is stronger — and our government more effective — when decision-makers reflect Canada’s diversity. The Government of Canada has implemented an appointment process that is transparent and merit-based, strives for gender parity, and ensures that Indigenous peoples and minority groups are properly represented in positions of leadership. We continue to search for Canadians who reflect the values that we all embrace: inclusion, honesty, fiscal prudence, and generosity of spirit. Together, we will build a government as diverse as Canada.
We are equally committed to providing a healthy workplace that supports one’s dignity, self-esteem and the ability to work to one’s full potential. With this in mind, all appointees will be expected to take steps to promote and maintain a healthy, respectful and harassment-free work environment.
The Government of Canada is currently seeking applications from diverse and talented Canadians from across the country who are interested in the following positions.
Current opportunities
The following opportunities for appointments to Governor in Council positions are currently open for applications. Every opportunity is open for a minimum of two weeks from the date of posting on the Governor in Council appointments website.
| Position | Organization | Closing date |
|---|---|---|
| Parliamentary Budget Officer | Office of the Parliamentary Budget Officer |
DEPARTMENT OF HEALTH
CONTROLLED DRUGS AND SUBSTANCES ACT
Notice of intent to control zuranolone under the Controlled Drugs and Substances Act
Purpose
This notice provides interested parties with the opportunity to comment on Health Canada’s proposal to control zuranolone by adding it to Schedule IV to the Controlled Drugs and Substances Act (CDSA). Zuranolone would also be regulated as a targeted substance to permit its legitimate use.footnote 1
Description
On December 5, 2025, Health Canada issued a market authorization for ZURZUVAE™, a prescription drug that contains the active ingredient zuranolone, for the treatment of moderate or severe postpartum depression in adults following childbirth. Zuranolonefootnote 2 (Chemical Abstracts Service Registry Number [CAS RN] 1632051) is a synthetic neuroactive steroid recently approved in Canada as an oral capsule formulation offered in 20 mg, 25 mg and 30 mg strengths. Zuranolone is not currently controlled under the CDSA.
Proposal to schedule zuranolone
The CDSA is the federal statute that provides a legislative framework for the control of substances that can alter mental processes and that may cause harm to the health of an individual or to society when diverted to an illegal market or is misused. Under the CDSA, certain activities with controlled substances and precursors are prohibited unless specifically authorized by its regulations or through an exemption.
When making a recommendation to schedule a substance, Health Canada conducts a comprehensive assessment that considers several factors, including international controls, chemical and pharmacological similarity to other substances listed in the Schedules to the CDSA, potential for misuse and/or addiction liability, evidence and extent of misuse of the substance, risk to personal and public health and safety, and legitimate use (e.g. medical, scientific, industrial).
Zuranolone is a positive allosteric modulator of gamma-aminobutyric acid type A (GABAA) receptor and shows potential for both misuse and physical dependence. According to the scientific assessment conducted by Health Canada, zuranolone presents similar risks to benzodiazepines, which are listed as item 18 in Schedule IV to the CDSA and are regulated as targeted substances under the Benzodiazepines and Other Targeted Substances Regulations.
Impact of proposed scheduling
If zuranolone is scheduled under the CDSA, anyone wanting to conduct activities with zuranolone would need to follow the requirements set out in the regulations. A controlled substances licence would be required to conduct various activities with zuranolone, such as produce, assemble, sell, provide, transport, send, deliver, import or export. Additionally, an import or export permit would be needed for each shipment of zuranolone into or out of Canada. Anyone wishing to conduct research or clinical trials with zuranolone would need to apply to Health Canada for an exemption.
Zuranolone is available in Canada by prescription only. This would continue to be the case if zuranolone is scheduled under the CDSA. Under the Food and Drug Regulations, there are different labelling requirements that apply to prescription drugs as opposed to targeted substances. Health Canada is proposing to provide a transitional period to minimize the impacts of the change in labelling requirements on the supply chain for this drug.
The increased oversight that would result from controlling zuranolone under the CDSA would help minimize its potential for misuse and diversion, and any potential risks to public health and safety. It would also provide law and border enforcement with additional tools to take action against any illegal importation, distribution, and production of the drug.
Public comment period
Comments received in response to this notice will inform the development of the proposed regulatory amendments. This consultation will be open until April 18, 2026. Health Canada encourages all interested parties to share their views.
Comments may be submitted by email to csd.regulatory.policy-politique.reglementaire.dsc@hc-sc.gc.ca, with the subject line “Consultation — Zuranolone.”